ViGeneron

ViGeneron is a pioneering gene therapy company focused on developing innovative treatments for ophthalmic diseases that currently lack effective therapies. The company operates in the biotechnology sector, specifically targeting eye diseases with high unmet medical needs. ViGeneron's core business model revolves around its three novel gene therapy platforms designed to overcome the limitations of existing adeno-associated virus (AAV) based therapies. These platforms aim to achieve superior delivery through less invasive administration routes, enable the delivery of large genes, and modulate the expression of multiple genes. The company generates revenue through partnerships, licensing agreements, and proprietary product development. ViGeneron serves a diverse client base, including patients, healthcare providers, and research institutions. The company secured significant funding in a Series A financing round in November 2019, backed by prominent investors WuXi AppTec and Sequoia Capital China. This funding is being utilized to accelerate the development of its viral vector-based gene therapy platforms and advance its ophthalmic gene therapy programs.

Keywords: gene therapy, ophthalmic diseases, AAV, viral vector, biotechnology, innovative treatments, large genes, gene modulation, Series A financing, proprietary platforms.